John B Bode insider trades: Zevra Therapeutics (ZVRA) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where John reports to the SEC
Open-market buys and sales
6 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 19, 2025 | ZVRA | ↑ Buy | 5,000 | $9.16 | $46K | Direct | Aug 20, 2025 (1d) |
| Mar 19, 2025 | ZVRA | ↑ Buy | 10,000 | $7.96 | $80K | Direct | Mar 21, 2025 (2d) |
| Jul 12, 2024 | ZVRA | ↑ Buy | 10,000 | $5.87 | $59K | Direct | Jul 15, 2024 (3d) |
| Sep 5, 2023 | ZVRA | ↑ Buy | 10,000 | $5.13 | $51K | Direct | Sep 6, 2023 (1d) |
| May 18, 2023 | ZVRA | ↑ Buy | 10,000 | $5.04 | $50K | Direct | May 19, 2023 (1d) |
| Nov 11, 2014 | TPUB | ↑ Buy | 3,000 | $16.99 | $51K | By IRA | Nov 12, 2014 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other ZVRA insiders
Open-market trades in the last 12 months
About John B Bode's insider trades
John B Bode is a director at Zevra Therapeutics (ZVRA). Since Nov 11, 2014, John has reported 6 open-market purchases worth $337K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (11 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ZVRA insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.